What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?
- Donald L. Batisky
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
There has been an evolution in the understanding of the treatment of hypertension in children and adolescents over the past decade. This has been fueled in part by the increased attention paid to the clinical problem, given the increasing numbers of children and adolescents being diagnosed with this condition. There has also been a growing number of clinical trials performed and completed that demonstrate the blood pressure (BP)-lowering effects of antihypertensives and the side effect profiles of these medications, and that has led to FDA-labeling of many antihypertensive medications for use in children and adolescents. However, none of these trials has provided definitive data on the optimal first line agent for this patient population. Clinical experience and other approaches discussed in this review are still necessary to guide treatment of hypertension in the young. The quest for the optimal antihypertensive agent is just beginning, and it is going to take some extraordinary effort to reach that goal.
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76. CrossRef
- Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42. CrossRef
- •• The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report, Pediatrics 2011, 128 (Supplement 5): S213–S256. Updated, comprehensive cardiovascular risk reduction guidelines; hypertension section similar to the Fourth Report.
- Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci. 2010;119:151–61. CrossRef
- Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20:791–7. CrossRef
- Podoll A, Grenier M, Croix B, Feig DI. Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics. 2007;119:e538–43. CrossRef
- Stewart JN, McGillivray D, Sussman J, Foster B. The value of routine blood pressure measurement in children presenting to the emergency department with nonurgent problems. J Pediatr. 2008;153:478–83. CrossRef
- Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol. 2009;24:1939–49. CrossRef
- Batisky DL. Obesity and the role of lifestyle and dietary intervention in the management of pediatric hypertension. J Med Liban. 2010;58:171–4.
- Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24:1101–12. CrossRef
- Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens. 2008;21:605–12. CrossRef
- Flynn JT, Falkner BE. Obesity hypertension in adolescents: epidemiology, evaluation, and management. J Clin Hypertens. 2011;13:323–31. CrossRef
- Batisky DL. Blood pressure variability, prehypertension, and hypertension in adolescents. Adolesc Health, Med Ther. 2012;3:1–8.
- Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003;289:2560–72. CrossRef
- •• Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484–90. Only recent clinical trial in pediatric hypertension comparing two different classes of agents. CrossRef
- Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiologic parameters. Med Hypoth. 2010;75:439–41. CrossRef
- Laragh JH. Abstract, closing summary, and table of contents for Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173–7. CrossRef
- Laragh JH, Sealey JE. The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin-Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. Am J Hypertens. 2011;24:1164–80. CrossRef
- Flynn JT. Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol. 2011;58:111–20. CrossRef
- Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5:330–55. CrossRef
- Flynn JT, Newburger JW, Daniels SW, et al. for the PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9. CrossRef
- •• Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14:383–7. This reference is a concise, well-organized, and current review of this topic. CrossRef
- Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20:990–6. CrossRef
- Wühl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–76. CrossRef
- •• Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Anti-hypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens. 2012;14:388–95. Demonstrates ongoing use of antihypertensive medications despite lack of FDA-approved pediatric labeling. CrossRef
- What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?
Current Hypertension Reports
Volume 14, Issue 6 , pp 603-607
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Blood pressure
- Antihypertensive medication
- Industry Sectors
- Donald L. Batisky (1) (2) (3)
- Author Affiliations
- 1. Department of Pediatrics, Emory University School of Medicine, 1648 Pierce Drive Northeast, Atlanta, GA, 30322, USA
- 2. Pediatric Hypertension Program, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA, 30322, USA
- 3. Emory-Children’s Center, 2015 Uppergate Drive NE, Atlanta, GA, 30322, USA